Nuvilex Announces Substantial Development in Pancreatic Cancer Research
Published: Jul 17, 2012
SILVER SPRING, Md., July 17, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a biotechnology provider of cell and gene therapy solutions, announced today a significant new development in pancreatic cancer research. Pancreatic tumor models in animals have not existed previously that accurately mimic human pancreatic cancer. This research advancement, accomplished by the Nuvilex subsidiary, Austrianova Singapore and their colleagues was just published in the journal PLoS One.